Research programme: neurodegenerative disorders therapeutics - CombinatoRx

Drug Profile

Research programme: neurodegenerative disorders therapeutics - CombinatoRx

Latest Information Update: 22 Sep 2010

Price : $50

At a glance

  • Originator CHDI; Zalicus
  • Developer CHDI; CombinatoRx; Zalicus
  • Class
  • Mechanism of Action Survival of motor neuron 1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Huntington's disease; Spinal muscular atrophy

Most Recent Events

  • 31 Dec 2007 Discontinued - Preclinical for Spinal muscular atrophy in USA (unspecified route)
  • 21 May 2007 Lead identification is ongoing
  • 31 Aug 2005 Preclinical trials in Spinal muscular atrophy in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top